Effects of ozurdex on intraocular pressure. A real life clinical practice study

Jiménez-Gómez, B.; Gonzalez-Montpetit, Maria Elena; Calduch, Alejandro Fonollosa; Banuelos, Antonio; Franco, Sonia Valsero

doi:10.1016/j.oftale.2015.10.009

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No statistically significant differences were observed in IOP measure- Dex implant in DME J Chhablani et al ments at the follow-up visits between patients with and without a history of glaucoma. 9 These findings suggests that Ozurdex can be safely used in eyes with history of steroid response safely, but with regular IOP check is mandatory. The possible explanation given is that dexamethasone, triamcinolone acetonide (TA), and fluocinolone acetonide activate different patterns of gene expression in human trabecular meshwork.…”

Section: Discussionmentioning

confidence: 89%

Dexamethasone implant in diabetic macular edema in real-life situations

Chhablani

Bansal

Veritti

et al. 2015

Eye

View full text Add to dashboard Cite

Purpose To report outcome of eyes with recalcitrant and naive eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone implants (Ozurdex) injection. Methods Retrospective multicenter data analysis of eyes with DME treated with Ozurdex implant and with minimum follow-up of at least one year after the first implant. Data collected included demographic details, history of presenting illness, past treatment history, clinical examination details including visual acuity at presentation, and follow-up with imaging and treatment details. Paired sample t-test was used to measure mean differences between pre-and postimplant values obtained at baseline and last follow-up. Results A total of 79 eyes (62 subjects) were included. Sixty-four eyes had been previously treated; 15 eyes were naive. Among the previously treated eyes, mean interval between first Ozurdex injection and any previous treatment was 7.69 ± 8.2 months. In naive eyes, the visual acuity improved from baseline 0.58 ± 0.25 to 0.44 ± 0.33 logMAR at last follow-up (P = 0.05). In eyes that had been previously treated, the improvement was from 0.65 ± 0.34 at baseline to 0.48 ± 0.35 logMAR (P = 0.01). Mean treatment-free interval was 6.5 ± 4.5 months. Nine eyes were steroid responder with controlled intraocular pressure (IOP), none showed any spike in IOP during the followup period. Conclusions Ozurdex implant could be a good alternative for recalcitrant as well as naive eyes with DME. The visual gain after initial implant injection was fairly maintained, with additional treatment usually after 6 months in naive eyes. Ozurdex appeared safe even in steroid responders with good control of IOP with antiglaucoma medications.

show abstract

Section: Discussionmentioning

confidence: 89%

Dexamethasone implant in diabetic macular edema in real-life situations

Chhablani

Bansal

Veritti

et al. 2015

Eye

View full text Add to dashboard Cite

show abstract

“…However, none of the study tried to find out if it varies with geographic region. Most of the previous studies were limited to one region [13,[15][16][17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations—GEODEX-IOP study

Sharma¹,

Kuppermann

Bandello

et al. 2019

Eye

View full text Add to dashboard Cite

Purpose To analyse the intraocular pressure rise after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations. Methods The medical charts of 294 dexamethasone implants between February 2011 and 2017 were reviewed retrospectively. South Asian (India), White (Europe, US and Israel) Latino (Argentina and Brazil) patient data was included in the study. Ocular hypertension (OHT) was defined as intraocular pressure of >25 mmHg or an increase of at least 10 mmHg from baseline. The main indications for treatment were diabetic macular edema (ME) (65.6%), retinal vein occlusion (26.5%), uveitis (7.8%). Results Amongst 294 intravitreal implants, ocular hypertension (>25 mmHg) was recorded in 0, 8 and 9.5% in White, Latino, and South Asian groups, respectively. However, IOP > 20 mmHg was recorded in 14%, 28% and 27% in White, Latino, and South Asian groups, respectively. Incidence of very high IOP (>35 mmHg) was lower in all geographical groups. It was 3% in Latino followed by 2% in South Asian group. Conclusion Latino and South Asian groups have higher IOP rise compared to White population. Most patients with elevated IOP fluctuate between 20-25 mmHg.

show abstract

Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world

et al. 2019

View full text Add to dashboard Cite

PurposeTo evaluate the long-term cumulative probability of intraocular pressure (IOP) elevation with the intravitreal dexamethasone implant (IDI) when used to treat different indications: diabetic macular edema, uveitis, retinal vein occlusion.Methods705 IDI injections (429 eyes) were assessed and Kaplan-Meier graphs were generated to assess: the probability of different levels of IOP elevation (IOP≥21, ≥25 or ≥35 mmHg), IOP change ≥10 mmHg, initiation of IOP-lowering treatment, glaucoma surgery, IOP change with repeat injections and IOP elevation in eyes with glaucoma and ocular hypertension (OHT).ResultsThe cumulative probability of IOP ≥21, ≥25 and ≥35 mmHg was 50%-60%, 25%-30% and 6%-7% at 12–24 months, respectively. The probability of initiating IOP-lowering medication was 31%-54% at 12–24 months. Glaucoma and OHT eyes had a higher probability of mild IOP elevation (≥21 mmHg, 65.1%, 75% and 57.8%, p = 0.01), yet a similar moderate (≥25 mmHg, 22.3%, 28% and 30.2%, p = 0.91) and severe elevation of IOP (≥35 mmHg, 3.7%, 7.1% and 4%, p = 0.71) as normal eyes. Glaucoma surgery was required in only 0.9% cases (4/429). At baseline, 8.8% of the treated eyes had glaucoma, 6.7% OHT and 16.9% were already on IOP-lowering medication.ConclusionsIn the long-term (24 months), IOP elevation is common, generally mild (30% IOP, ≥25 mmHg) and well-tolerated, resolving with topical treatment (54%) and rarely requiring surgery (0.9%).

show abstract

Effects of ozurdex on intraocular pressure. A real life clinical practice study

Cited by 4 publications

References 6 publications

Dexamethasone implant in diabetic macular edema in real-life situations

Dexamethasone implant in diabetic macular edema in real-life situations

Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations—GEODEX-IOP study

Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world

Contact Info

Product

Resources

About